1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-1733. PMID:
16983459.
2. Russell LA. Osteoporosis and osteomalacia. Rheum Dis Clin North Am 2010;36:665-680. PMID:
21092845.
3. Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. Can Fam Physician 2012;58:158-162. PMID:
22439169.
4. Liperoti R, Onder G, Lapane KL, Mor V, Friedman JH, Bernabei R, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry 2007;68:929-934. PMID:
17592919.
5. Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2009;20:1499-1506. PMID:
19156348.
6. Jalbert JJ, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc 2010;11:120-127. PMID:
20142067.
8. Roke Y, van Harten PN, Buitelaar JK, Tenback DE, Quekel LG, de Rijke YB, et al. Bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment. Eur J Endocrinol 2012;167:855-863. PMID:
23011870.
9. O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008;22(2 Suppl):70-75. PMID:
18477623.
10. Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, Teerapornpuntakit J, et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 2008;42:535-546. PMID:
18166509.
11. Motyl KJ, Dick-de-Paula I, Maloney AE, Lotinun S, Bornstein S, de Paula FJ, et al. Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. Bone 2012;50:490-498. PMID:
21854880.
12. Sugawara N, Yasui-Furukori N, Fujii A, Saito M, Sato Y, Nakagami T, et al. No association between bone mass and prolactin levels among patients with schizophrenia. Hum Psychopharmacol 2011;26:596-601. PMID:
22105774.
13. Baastrup PC, Christiansen C, Transbol I. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology 1980;6:56-59. PMID:
6102745.
14. Nechifor M, Vaideanu C, Palamaru I, Borza C, Mindreci I. The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia. J Am Coll Nutr 2004;23:549S-551S. PMID:
15466963.
15. Wyszogrodzka-Kucharska A, Rabe-Jablonska J. Calcium balance and regulation in schizophrenic patients treated with second generation antipsychotics. Psychiatr Pol 2005;39:1157-1171. PMID:
16526182.
16. Zornic N, Jovanovic Radojevic D, Jankovic S, Djuric D, Varjacic M, Simic VD, et al. Monitoring of drug-associated electrolyte disturbances in a hospital. Pharmacoepidemiol Drug Saf 2009;18:1026-1033. PMID:
19655334.
17. Milovanovic DR, Janjic V, Zornic N, Djukic Dejanovic S, Jankovic SM. Risperidone-associated hypocalcemia. Am J Psychiatry 2010;167:1533-1534. PMID:
21131411.
18. Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 2012;25:415-429. PMID:
22744405.
19. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008;337:a1227PMID:
18755769.
20. Keks NA, Hope J. Long-term management of people with psychotic disorders in the community. Aust Prescr 2007;30:44-46.
21. Morgan JL, Skulan JL, Gordon GW, Romaniello SJ, Smith SM, Anbar AD. Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes. Proc Natl Acad Sci U S A 2012;109:9989-9994. PMID:
22652567.
22. James MT, Zhang J, Lyon AW, Hemmelgarn BR. Derivation and internal validation of an equation for albumin-adjusted calcium. BMC Clin Pathol 2008;8:12PMID:
19038049.
23. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington DC: National Osteoporosis Foundation; 2010.
24. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 11th Edition. Chichester: Wiley Blackwell; 2012.
25. Benrimoj SI, Langford JH, Christian J, Charlesworth A, Steans A. Efficacy and tolerability of the anti-inflammatory throat lozenge flurbiprofen 8.75 mg in the treatment of sore throat: a randomised, double-blind, placebo-controlled study. Clin Drug Invest 2001;21:183-193.
26. Favus MJ. Mineral and Bone Homeostasis. In: Goldman L, Ausiello D, editor. Cecil Medicine. 23rd Edition. Philadelphia: Saunders Elsevier, 2008, p. 1871-1879.
27. Schoeber JP, Hoenderop JG, Bindels RJ. Concerted action of associated proteins in the regulation of TRPV5 and TRPV6. Biochem Soc Trans 2007;35(Pt 1):115-119. PMID:
17233615.
28. Itzhaky D, Amital D, Gorden K, Bogomolni A, Arnson Y, Amital H. Low serum vitamin D concentrations in patients with schizophrenia. Isr Med Assoc J 2012;14:88-92. PMID:
22693787.
29. Jamilian H, Bagherzadeh K, Nazeri Z, Hassanijirdehi M. Vitamin D, parathyroid hormone, serum calcium and phosphorus in patients with schizophrenia and major depression. Int J Psychiatry Clin Pract 2013;17:30-34. PMID:
22536888.
30. Skouroliakou M, Giannopoulou I, Maria SG, Kostara C, Koutri K, Kakavelaki C. Vitamin D insufficiency in obese patients with severe mental illness taking olanzapine. Med J Nutrition Metab 2012;5:219-225.
31. Henry HL. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 2011;25:531-541. PMID:
21872796.
32. Daskalopoulos EP, Lang MA, Marselos M, Malliou F, Konstandi M. D
2-dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D. Mol Pharmacol 2012;82:668-678. PMID:
22772593.
33. Wojcikowski J, Haduch A, Daniel WA. Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacol Rep 2012;64:1411-1418. PMID:
23406751.
34. Martin A, Quarles LD. Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis. Adv Exp Med Biol 2012;728:65-83. PMID:
22396162.
35. Wu J, Carter A. Magnesium: the forgotten electrolyte. Aust Prescr 2007;30:102-105.
36. Liamis G, Milinos HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab 2009;27:635-642. PMID:
19730969.
37. Liamis G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia: a review. QJM 2010;103:449-459. PMID:
20356849.
38. Delva NJ, Crammer JL, Jarzylo SV, Lawson JS, Owen JA, Sribney M, et al. Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol Psychiatry 1989;26:781-793. PMID:
2590692.
39. Vetter T, Lohse MJ. Magnesium and the parathyroid. Curr Opin Nephrol Hypertens 2002;11:403-410. PMID:
12105390.
40. Higuchi T, Komoda T, Sugishita M, Yamazaki J, Miura M, Sakagishi Y, et al. Certain neuroleptics reduce bone mineralization in schizophrenic patients. Neuropsychobiology 1987;18:185-188. PMID:
2900482.
41. Sahota O, Mundey MK, San P, Godber IM, Hosking DJ. Vitamin D insufficiency and the blunted PTH response in established osteoporosis: the role of magnesium deficiency. Osteoporos Int 2006;17:1013-1021. PMID:
16596461.
42. Huang C, Miller RT. Regulation of renal ion transport by the calcium-sensing receptor: an update. Curr Opin Nephrol Hypertens 2007;16:437-443. PMID:
17693759.
44. Doknic M, Maric NP, Britvic D, Pekic S, Damjanovic A, Miljic D, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology 2011;94:246-254. PMID:
21986470.
45. Labad J, Stojanovic-Perez A, Montalvo I, Sole M, Cabezas A, Ortega L, et al. Stress biomarkers as predictors of transition to psychosis in at-risk mental states: roles for cortisol, prolactin and albumin. J Psychiatr Res 2015;60:163-169. PMID:
25466832.
46. Vlahovic Z, Radojkovic D. Healthcare in Serbia in transition period. EPMA J 2010;1:601-606. PMID:
23199113.
47. Tugwell P, Haynes B. Assessing Claims of Causation. In: Haynes RB, Sackett DL, Guyatt GH, Tugwell P, editor. Clinical Epidemiology - How to Do Clinical Practice Research. 3rd Edition. Philadelphia: Lippincot Williams & Wilkins, 2006, p. 356-387.
48. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208. PMID:
15206667.